Northfield Laboratories: Difference between revisions
Add banner {{Cleanup bare URLs}}. After at least 7 passes by @Citation bot since 20220802 + more before then, this article still has 1 untagged bare URL ref |
Citation bot (talk | contribs) Alter: title. | Use this bot. Report bugs. | Suggested by Abductive | Category:Companies formerly listed on the Nasdaq | #UCB_Category 676/712 |
||
| Line 69: | Line 69: | ||
'''Northfield Laboratories Inc.''' ( former NASDAQ: '''NFLD''' ) was the maker of [[PolyHeme]], a [[Hemoglobin-based oxygen carriers|hemoglobin-based oxygen carrier]] (HBOC). The company was based in [[Evanston, Illinois]], with Dr. Steven A. Gould as its [[chief executive officer]]. As of May 31, 2005, the company had 68 employees. |
'''Northfield Laboratories Inc.''' ( former NASDAQ: '''NFLD''' ) was the maker of [[PolyHeme]], a [[Hemoglobin-based oxygen carriers|hemoglobin-based oxygen carrier]] (HBOC). The company was based in [[Evanston, Illinois]], with Dr. Steven A. Gould as its [[chief executive officer]]. As of May 31, 2005, the company had 68 employees. |
||
It was founded in 1985 and has since been a mainly [[research and development]] company. Northfield's only product was PolyHeme, an oxygen-carrying [[blood substitute]], which failed to receive [[Food and Drug Administration]] (FDA) regulatory approval. On May 9, 2009, after being informed by the FDA the product's risks outweighed the benefits, the company shut down operations. During their operations, they incurred losses of about 220 million dollars.<ref>{{cite web |url=http://www.chicagotribune.com/business/chi-sat-northfield-0509-may09,0,1111961.story |title= |website=www.chicagotribune.com |access-date=May 9, 2009}}{{SemiBareRefNeedsTitle|date=May 2022}}</ref> |
It was founded in 1985 and has since been a mainly [[research and development]] company. Northfield's only product was PolyHeme, an oxygen-carrying [[blood substitute]], which failed to receive [[Food and Drug Administration]] (FDA) regulatory approval. On May 9, 2009, after being informed by the FDA the product's risks outweighed the benefits, the company shut down operations. During their operations, they incurred losses of about 220 million dollars.<ref>{{cite web |url=http://www.chicagotribune.com/business/chi-sat-northfield-0509-may09,0,1111961.story |title= Business News|website=www.chicagotribune.com |access-date=May 9, 2009}}{{SemiBareRefNeedsTitle|date=May 2022}}</ref> |
||
The corporation was also criticized for some design elements of its clinical trials related to the need to perform critical care and resuscitation while patients were in grave clinical conditions due to the mechanisms of injury incurred and the consequent inability of patients to provide informed consent for treatment.<ref>http://blogs.abcnews.com/theblotter/2007/05/test_of_controv.html</ref> |
The corporation was also criticized for some design elements of its clinical trials related to the need to perform critical care and resuscitation while patients were in grave clinical conditions due to the mechanisms of injury incurred and the consequent inability of patients to provide informed consent for treatment.<ref>http://blogs.abcnews.com/theblotter/2007/05/test_of_controv.html</ref> |
||
Revision as of 20:42, 17 November 2022
 |
 | This article needs additional citations for verification. (November 2019) |
| Founded | 1985 |
|---|---|
| Defunct | May 9, 2009 |
| Headquarters | |
| Products | PolyHeme |
Northfield Laboratories Inc. ( former NASDAQ: NFLD ) was the maker of PolyHeme, a hemoglobin-based oxygen carrier (HBOC). The company was based in Evanston, Illinois, with Dr. Steven A. Gould as its chief executive officer. As of May 31, 2005, the company had 68 employees.
It was founded in 1985 and has since been a mainly research and development company. Northfield's only product was PolyHeme, an oxygen-carrying blood substitute, which failed to receive Food and Drug Administration (FDA) regulatory approval. On May 9, 2009, after being informed by the FDA the product's risks outweighed the benefits, the company shut down operations. During their operations, they incurred losses of about 220 million dollars.[1] The corporation was also criticized for some design elements of its clinical trials related to the need to perform critical care and resuscitation while patients were in grave clinical conditions due to the mechanisms of injury incurred and the consequent inability of patients to provide informed consent for treatment.[2]
See also
References
- ^ "Business News". www.chicagotribune.com. Retrieved May 9, 2009.Template:SemiBareRefNeedsTitle
- ^ http://blogs.abcnews.com/theblotter/2007/05/test_of_controv.html
External links
 | This chemical corporation-related article is a stub. You can help Wikipedia by expanding it. |
 | This United States corporation or company article is a stub. You can help Wikipedia by expanding it. |